Cargando…

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

AIM: In cancer immunotherapy, biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination. MATERIALS & METHODS: Candidate genes that were expressed differentially between long- and short-term...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takashima, Satoshi, Oka, Yoshihiro, Fujiki, Fumihiro, Morimoto, Soyoko, Nakajima, Hiroko, Nakae, Yoshiki, Nakata, Jun, Nishida, Sumiyuki, Hosen, Naoki, Tatsumi, Naoya, Mizuguchi, Kenji, Hashimoto, Naoya, Oji, Yusuke, Tsuboi, Akihiro, Kumanogoh, Atsushi, Sugiyama, Haruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241910/ https://www.ncbi.nlm.nih.gov/pubmed/28116121 http://dx.doi.org/10.4155/fsoa-2015-0008

Ejemplares similares

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells
por: Hasegawa, Kana, et al.
Publicado: (2015)

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
por: Tsuboi, Akihiro, et al.
Publicado: (2018)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
por: Nakata, Jun, et al.
Publicado: (2018)

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2022)

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
por: Alzaaqi, Shouq, et al.
Publicado: (2022)

Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT
por: Nakata, Jun, et al.
Publicado: (2020)

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers
por: Oka, Yoshihiro, et al.
Publicado: (2007)

Imaging Assessment of Tumor Response in the Era of Immunotherapy
por: Nakata, Jun, et al.
Publicado: (2021)

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis
por: Hasegawa, Kana, et al.
Publicado: (2016)

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity
por: Morimoto, Soyoko, et al.
Publicado: (2018)

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments
por: Nishida, Sumiyuki, et al.
Publicado: (2019)

T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy
por: Fujiki, Fumihiro, et al.
Publicado: (2022)

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs
por: Fujiki, Fumihiro, et al.
Publicado: (2023)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2014)

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine
por: Maeda, T, et al.
Publicado: (2013)

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
por: Minagawa, Hikaru, et al.
Publicado: (2023)

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review
por: Hashii, Yoshiko, et al.
Publicado: (2020)

IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
por: Kagawa, Naoki, et al.
Publicado: (2019)

Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
por: Oji, Yusuke, et al.
Publicado: (1999)

The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
por: OJI, YUSUKE, et al.
Publicado: (2014)

Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma
por: Andersson, Charlotta, et al.
Publicado: (2014)

Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies
por: Yokota, Chisato, et al.
Publicado: (2021)

Comparative immunohistochemical analysis of WT-1, Syndecan and Snail in Ameloblastoma and odontogenic keratocyst: A retrospective study
por: Mukhopadhyay, Arka, et al.
Publicado: (2023)

The Wilms' Tumor Gene WT1 − 17AA/− KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model
por: Yamanouchi, Keiko, et al.
Publicado: (2014)

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
por: Versteven, Maarten, et al.
Publicado: (2018)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer
por: Ito, Masaaki, et al.
Publicado: (2022)

Syndecan-3 and syndecan-4 are enriched in Schwann cell perinodal processes
por: Goutebroze, Laurence, et al.
Publicado: (2003)

Reduced Expression of Syndecan‐1 Affects Metastatic Potential and Clinical Outcome in Patients with Colorectal Cancer
por: Fujiya, Mikihiro, et al.
Publicado: (2001)

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2017)

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2021)

Syndecan-Regulated Receptor Signaling
por: Rapraeger, Alan C.
Publicado: (2000)

Syndecan-3 gets the message
por: Leslie, Mitch
Publicado: (2011)

The Cardiac Syndecan-2 Interactome
por: Mathiesen, Sabrina Bech, et al.
Publicado: (2020)

Syndecan-3 in Inflammation and Angiogenesis
por: Arokiasamy, Samantha, et al.
Publicado: (2020)

Syndecans in Inflammation at a Glance
por: Gopal, Sandeep
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kgq8qroqroe8jagm9l05qta4jt